


REMARKS


Claims 1 to 86 and new claims 87 and 88 appear in this application for the Examiner's review and consideration. The new claims are fully supported by the specification and claims as originally filed. In particular, support for new claims 87 and 88 can be found in paragraph [0066] on page 22 to the specification. Therefore, there is no issue of new matter. Claims 23 to 27 and 59 to 63 are withdrawn from consideration at this time, as not being directed to the elected species.

Election of a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable was required under 35 U.S.C. 121, for the reasons set forth on pages 2 to 5 of the Office Action. Election of one of ligands (I) to (XVIII), set forth on pages 2 and 3 of the Office Action, one of compounds (A) to (E), set forth on page 3 of the Office Action, and a metal selected from those recited in claim 5 was required. Election of an ultimate species was also required.

In response, Applicants elect the compound



as the ultimate species to be used as the starting point for search and examination purposes. Therefore, Applicants elect ligand (I),



the first formula of page 20 of the specification; the compound (E), having at least two ligands that are different, at least one ligand selected from (I)-(XVII), and at least one ligand is selected from (XVIII), i.e., a ligand other than (I)-(XVII); and the metal iridium for

prosecution on the merits at this time. The ligand (XVIII) in the elected ultimate species is 2-phenylpyridine.

Claims 1 to 22, 28 to 58, and 64 to 86 read on the elected species. New claims 87 and 88 are generic.


Applicants submit that the entire application is in condition for allowance, an early notice of which would be appreciated. Should the Examiner not agree with Applicants' position, a personal or telephonic interview is respectfully requested to discuss any remaining issues prior to the issuance of a further Office Action, and to expedite the allowance of the application.

A separate claim fee sheet is attached. Should any other fees be due, however, please charge such fees to Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON LLP

Dated: July 20, 2006

By: 
Alan P. Force
Reg. No. 39,673
One Broadway
New York, NY 10004
Tel: (212) 425-7200
CUSTOMER NUMBER 26646

NY01 1196549 v1